FDA Expands EUA for SBECD-enabled Remdesivir
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With
Tag: FDA
FDA Approves New KYPROLIS® (SBECD-enabled carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone
Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma Amgen today announced the U.S. Food and
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it
Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD
Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Az amerikai gyógyszerhatóság (FDA) engedélyezte a ciklodextrinnel formulázott remdesivir használatát COVID-19 kezelésére
A Gilead Sciences, Inc. amerikai gyógyszercég tegnap bejelentette, hogy a U.S. Food and Drug Administration (FDA, amerikai gyógyszerhatóság) úgynevezett “emergency
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Hundreds of Virus Patients Allowed to Try Gilead’s Ebola Drug
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today